|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Q, Liu HY, Liu D and Song YQ:
Ultrasonographic features of triple-negative breast cancer: A
comparison with other breast cancer subtypes. Asian Pac J Cancer
Prev. 16:3229–3232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reisman D, Glaros S and Thompson EA: The
SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phelan ML, Sif S, Narlikar GJ and Kingston
RE: Reconstitution of a core chromatin remodeling complex from
SWI/SNF subunits. Mol Cell. 3:247–253. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Inoue H, Furukawa T, Giannakopoulos S,
Zhou S, King DS and Tanese N: Largest subunits of the human SWI/SNF
chromatin-remodeling complex promote transcriptional activation by
steroid hormone receptors. J Biol Chem. 277:41674–41685. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagl NG Jr, Wang X, Patsialou A, Van Scoy
M and Moran E: Distinct mammalian SWI/SNF chromatin remodeling
complexes with opposing roles in cell-cycle control. EMBO J.
26:752–763. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoyer J, Ekici AB, Endele S, Popp B,
Zweier C, Wiesener A, Wohlleber E, Dufke A, Rossier E, Petsch C, et
al: Haploinsufficiency of ARID1B, a member of the SWI/SNF-a
chromatin-remodeling complex, is a frequent cause of intellectual
disability. Am J Hum Genet. 90:565–572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sausen M, Leary RJ, Jones S, Wu J,
Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr,
Papadopoulos N, et al: Integrated genomic analyses identify ARID1A
and ARID1B alterations in the childhood cancer neuroblastoma. Nat
Genet. 45:12–17. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: The landscape of cancer genes and mutational processes
in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shao F, Guo T, Chua PJ, Tang L, Thike AA,
Tan PH, Bay BH and Baeg GH: Clinicopathological significance of
ARID1B in breast invasive ductal carcinoma. Histopathology.
67:709–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khursheed M, Kolla JN, Kotapalli V, Gupta
N, Gowrishankar S, Uppin SG, Sastry RA, Koganti S, Sundaram C,
Pollack JR and Bashyam MD: ARID1B, a member of the human SWI/SNF
chromatin remodeling complex, exhibits tumour-suppressor activities
in pancreatic cancer cell lines. Br J Cancer. 108:2056–2062. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berger AM, Mooney K, Alvarez-Perez A,
Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E,
Eisenberger MA, Escalante CP, et al: Cancer-Related Fatigue,
Version 2.2015. J Natl Compr Canc Netw. 13:1012–1039. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kobayashi T, Iwaya K, Moriya T, Yamasaki
T, Tsuda H, Yamamoto J and Matsubara O: A simple
immunohistochemical panel comprising 2 conventional markers, Ki67
and p53, is a powerful tool for predicting patient outcome in
luminal-type breast cancer. BMC Clin Pathol. 13:52013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asleh-Aburaya K and Fried G: Clinical and
molecular characteristics of triple-negative breast cancer patients
in Northern Israel: Single center experience. Springerplus.
4:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weissman B and Knudsen KE: Hijacking the
chromatin remodeling machinery: Impact of SWI/SNF perturbations in
cancer. Cancer Res. 69:8223–8230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilson BG and Roberts CW: SWI/SNF
nucleosome remodellers and cancer. Nat Rev Cancer. 11:481–492.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Nagl NG, Wilsker D, Van Scoy M,
Pacchione S, Yaciuk P, Dallas PB and Moran E: Two related ARID
family proteins are alternative subunits of human SWI/SNF
complexes. Biochem J. 383:319–325. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao J, Liu C and Zhao Z: ARID1A: A
potential prognostic factor for breast cancer. Tumour Biol.
35:4813–4819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mamo A, Cavallone L, Tuzmen S, Chabot C,
Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O,
Przybytkowski E, et al: An integrated genomic approach identifies
ARID1A as a candidate tumor-suppressor gene in breast cancer.
Oncogene. 31:2090–2100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guan B, Gao M, Wu CH, Wang TL and Shih Ie
M: Functional analysis of in-frame indel ARID1A mutations reveals
new regulatory mechanisms of its tumor suppressor functions.
Neoplasia. 14:986–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu JN and Roberts CW: ARID1A mutations in
cancer: Another epigenetic tumor suppressor? Cancer Discov.
3:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flores-Alcantar A, Gonzalez-Sandoval A,
Escalante-Alcalde D and Lomeli H: Dynamics of expression of ARID1A
and ARID1B subunits in mouse embryos and in cells during the cell
cycle. Cell Tissue Res. 345:137–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sim JC, White SM, Fitzpatrick E, Wilson
GR, Gillies G, Pope K, Mountford HS, Torring PM, McKee S, Vulto-van
Silfhout AT, et al: Expanding the phenotypic spectrum of
ARID1B-mediated disorders and identification of altered cell-cycle
dynamics due to ARID1B haploinsufficiency. Orphanet J Rare Dis.
9:432014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Inghirami G, Chiarle R, Simmons WJ, Piva
R, Schlessinger K and Levy DE: New and old functions of STAT3: A
pivotal target for individualized treatment of cancer. Cell Cycle.
4:1131–1133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Helming KC, Wang X, Wilson BG, Vazquez F,
Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ,
et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Nat Med. 20:251–254. 2014. View
Article : Google Scholar : PubMed/NCBI
|
